Table 1.
Background information on participants contributing to the PRACTICAL Consortium by study
| Age at diagnosis | PSA level at diagnosis (ng/ml) | Family history | Gleason score | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study | Country | Controls | Cases | Mean | SD | Median | Lower quartile | Upper quartile | of disease | 8–10 |
| CAPS | Sweden | 664 | 1,153 | 66.10 | 7.75 | 13.0 | 7.0 | 30.0 | 17.35% | 15.26% |
| CPCS1 | Denmark | 2,771 | 848 | 69.51 | 7.91 | 15.0 | 8.0 | 37.5 | 8.21% | 26.65% |
| CPCS2 | Denmark | 1,009 | 265 | 64.88 | 6.82 | 9.0 | 6.0 | 14.5 | 14.72% | 9.06% |
| EPIC | Europe | 1,079 | 722 | 64.87 | 5.62 | 8.6 | 6.0 | 15.9 | – | 2.22% |
| EPIC‐Norfolk | UK | 917 | 484 | 72.08 | 7.56 | 19.8 | 19.8 | 19.8 | 2.48% | 1.86% |
| ESTHER | Germany | 318 | 313 | 65.52 | 5.09 | 6.9 | 5.0 | 14.0 | 10.54% | 8.63% |
| FHCRC | USA | 730 | 761 | 59.73 | 7.18 | 6.4 | 4.7 | 9.8 | 21.68% | 10.38% |
| IPO‐Porto | Portugal | 66 | 183 | 59.33 | 5.23 | 7.4 | 5.5 | 10.1 | 20.00% | 15.85% |
| MAYO | USA | 488 | 767 | 65.24 | 6.42 | 7.8 | 4.9 | 14.7 | 29.07% | 28.42% |
| MCCS | Australia | 1,170 | 1,698 | 58.45 | 8.46 | 5.4 | 0.0 | 11.4 | 23.45% | 10.31% |
| MEC | USA | 829 | 819 | 69.53 | 7.62 | – | – | – | 13.03% | 34.55% |
| MOFFITT | USA | 100 | 414 | 64.97 | 8.27 | 5.6 | 4.3 | 7.4 | 22.76% | 11.11% |
| PCMUS | Bulgaria | 140 | 151 | 69.27 | 8.71 | 15.8 | 7.4 | 34.0 | 5.30% | 29.80% |
| PPF‐UNIS | UK | 188 | 245 | 68.86 | 7.57 | 8.6 | 6.3 | 14.0 | 25.22% | 9.39% |
| Poland | Poland | 359 | 438 | 67.66 | 7.84 | 11.0 | 6.9 | 26.0 | 10.57% | 11.42% |
| ProMPT | UK | 0 | 166 | 66.33 | 8.64 | 8.8 | 5.7 | 15.3 | 34.62% | 16.87% |
| ProtecT | UK | 1,474 | 1,542 | 62.76 | 5.11 | 5.1 | 3.8 | 8.2 | 7.91% | 5.64% |
| QLD | Australia | 87 | 186 | 61.32 | 6.91 | 5.2 | 2.2 | 7.5 | 36.18% | 3.76% |
| SEARCH | UK | 1,244 | 1,371 | 63.08 | 4.76 | 8.8 | 5.6 | 15.0 | 16.24% | 10.14% |
| STHM1 | Sweden | 2,224 | 2,006 | 66.17 | 6.99 | – | – | – | 20.18% | 7.93% |
| TAMPERE | Finland | 2,413 | 2,754 | 68.18 | 7.96 | 8.6 | 5.6 | 16.3 | – | 13.76% |
| UKGPCS | UK | 4,182 | 4,549 | 63.76 | 7.97 | 9.8 | 5.6 | 24.7 | 23.42% | 14.13% |
| ULM | Germany | 354 | 603 | 63.78 | 6.66 | 9.0 | 6.0 | 15.1 | 44.94% | 12.11% |
| UTAH | USA | 245 | 440 | 62.57 | 8.85 | – | – | – | 51.36% | 15.45% |
| WUGS | USA | 0 | 990 | 60.80 | 7.03 | 5.0 | 4.0 | 7.0 | 42.43% | 7.88% |
Abbreviations: SD, standard deviation; PSA, prostate‐specific antigen.